SANUWAVE Q1 revenue up 18% to $3.8M; operating loss flat at $2.0M

SANUWAVE Health, Inc.

2023-Q1 EPS reported -$0.02 revenue$3,775,000

Revenue $3.8M (+18% YoY) within prior guidance; gross margin fell to 67% from 72%.
UltraMist systems sold 28 (+12% YoY); applicator cases 3,641 (+18% YoY).
Operating loss $2.0M, unchanged YoY; no net income/(loss) figure disclosed.
Post-quarter raised ~$1.2M via terms consistent with prior financing; funds not in Q1 statements.
Q2 revenue growth guided to 15-25% YoY, citing improving inventory supply.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANUWAVE Health, Inc. reported first quarter ended March 31, 2023 results: revenue $3.8 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $3.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results. For the three-months ended March 31, 2023: • Revenues increased 18% to $3.8 million for Q1 2023 versus $3.2 million for the same period last year.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-024283

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.